HUM vs TEVA: Which Stock Is the Better Buy?
Humana Inc. and Teva Pharmaceutical Industries Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — HUM vs TEVA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Humana Inc. (HUM) | Teva Pharmaceutical Industries Limited (TEVA) | |
|---|---|---|
| Market cap | $43.7B | $40.1B |
| Revenue (latest FY) | $129.66B | $17.26B |
| Net income (latest FY) | $1.19B | $1.41B |
| Revenue growth (5y CAGR) | 10.9% | 0.7% |
| Net margin | 0.9% | 8.2% |
| Return on equity | 6.7% | 17.8% |
| P/E ratio | 34.4 | 25.7 |
| Dividend yield | 1.0% | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full HUM vs TEVA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open HUM's full financials → Open TEVA's full financials →Frequently asked questions
Which is bigger, HUM or TEVA?
Humana Inc. is larger by market capitalization — $43.7B versus $40.1B.
Which grows faster, HUM or TEVA?
Over the last five fiscal years, Humana Inc. grew revenue faster — 10.9%/yr versus 0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
HUM fundamentals → · TEVA fundamentals → · All 1,500+ companies → · Free screener →